Articles producció científica> Bioquímica i Biotecnologia

Exploring small non-coding RNAs as blood-based biomarkers to predict Alzheimer's disease

  • Identification data

    Identifier: imarina:9334947
    Authors:
    Gutierrez-Tordera, LaiaPapandreou, ChristopherNovau-Ferre, NilGarcia-Gonzalez, PabloRojas, MelinaMarquie, MartaChapado, Luis APapagiannopoulos, ChristosFernandez-Castillo, NoeliaValero, SergiFolch, JaumeEttcheto, MirenCamins, AntoniBoada, MerceRuiz, AgustinBullo, Monica
    Abstract:
    Alzheimer's disease (AD) diagnosis relies on clinical symptoms complemented with biological biomarkers, the Amyloid Tau Neurodegeneration (ATN) framework. Small non-coding RNA (sncRNA) in the blood have emerged as potential predictors of AD. We identified sncRNA signatures specific to ATN and AD, and evaluated both their contribution to improving AD conversion prediction beyond ATN alone.This nested case-control study was conducted within the ACE cohort and included MCI patients matched by sex. Patients free of type 2 diabetes underwent cerebrospinal fluid (CSF) and plasma collection and were followed-up for a median of 2.45-years. Plasma sncRNAs were profiled using small RNA-sequencing. Conditional logistic and Cox regression analyses with elastic net penalties were performed to identify sncRNA signatures for A+(T|N)+ and AD. Weighted scores were computed using cross-validation, and the association of these scores with AD risk was assessed using multivariable Cox regression models. Gene ontology (GO) and Kyoto encyclopaedia of genes and genomes (KEGG) enrichment analysis of the identified signatures were performed.The study sample consisted of 192 patients, including 96 A+(T|N)+ and 96 A-T-N- patients. We constructed a classification model based on a 6-miRNAs signature for ATN. The model could classify MCI patients into A-T-N- and A+(T|N)+ groups with an area under the curve of 0.7335 (95% CI, 0.7327 to 0.7342). However, the addition of the model to conventional risk factors did not improve the prediction of AD beyond the conventional model plus ATN status (C-statistic: 0.805 [95% CI, 0.758 to 0.852] compared to 0.829 [95% CI, 0.786, 0.872]). The AD-related 15-sncRNAs signature exhibited better predictive performance than the conventional model plus ATN status (C-stati
  • Others:

    Author, as appears in the article.: Gutierrez-Tordera, Laia; Papandreou, Christopher; Novau-Ferre, Nil; Garcia-Gonzalez, Pablo; Rojas, Melina; Marquie, Marta; Chapado, Luis A; Papagiannopoulos, Christos; Fernandez-Castillo, Noelia; Valero, Sergi; Folch, Jaume; Ettcheto, Miren; Camins, Antoni; Boada, Merce; Ruiz, Agustin; Bullo, Monica
    Department: Bioquímica i Biotecnologia
    URV's Author/s: Bulló Bonet, Mònica / Folch Lopez, Jaume / GUTIERREZ TORDERA, LAIA / Novau Ferré, Nil / Rojas Criollo, Melina Isabella
    Keywords: Small non-coding rna Potential biomarkers Nested case–control study Mild cognitive impairment Gene regulatory networks Biomarkers Atn Alzheimer’s disease Alzheimer's disease tau small non-coding rna performance nested case-control study mirnas mild cognitive impairment gene regulatory networks expression diagnosis biomarkers atn
    Abstract: Alzheimer's disease (AD) diagnosis relies on clinical symptoms complemented with biological biomarkers, the Amyloid Tau Neurodegeneration (ATN) framework. Small non-coding RNA (sncRNA) in the blood have emerged as potential predictors of AD. We identified sncRNA signatures specific to ATN and AD, and evaluated both their contribution to improving AD conversion prediction beyond ATN alone.This nested case-control study was conducted within the ACE cohort and included MCI patients matched by sex. Patients free of type 2 diabetes underwent cerebrospinal fluid (CSF) and plasma collection and were followed-up for a median of 2.45-years. Plasma sncRNAs were profiled using small RNA-sequencing. Conditional logistic and Cox regression analyses with elastic net penalties were performed to identify sncRNA signatures for A+(T|N)+ and AD. Weighted scores were computed using cross-validation, and the association of these scores with AD risk was assessed using multivariable Cox regression models. Gene ontology (GO) and Kyoto encyclopaedia of genes and genomes (KEGG) enrichment analysis of the identified signatures were performed.The study sample consisted of 192 patients, including 96 A+(T|N)+ and 96 A-T-N- patients. We constructed a classification model based on a 6-miRNAs signature for ATN. The model could classify MCI patients into A-T-N- and A+(T|N)+ groups with an area under the curve of 0.7335 (95% CI, 0.7327 to 0.7342). However, the addition of the model to conventional risk factors did not improve the prediction of AD beyond the conventional model plus ATN status (C-statistic: 0.805 [95% CI, 0.758 to 0.852] compared to 0.829 [95% CI, 0.786, 0.872]). The AD-related 15-sncRNAs signature exhibited better predictive performance than the conventional model plus ATN status (C-statistic: 0.849 [95% CI, 0.808 to 0.890]). When ATN was included in this model, the prediction further improved to 0.875 (95% CI, 0.840 to 0.910). The miRNA-target interaction network and functional analysis, including GO and KEGG pathway enrichment analysis, suggested that the miRNAs in both signatures are involved in neuronal pathways associated with AD.The AD-related sncRNA signature holds promise in predicting AD conversion, providing insights into early AD development and potential targets for prevention.© 2024. The Author(s).
    Thematic Areas: Medicina ii General biochemistry,genetics and molecular biology Biochemistry, genetics and molecular biology (miscellaneous) Biochemistry, genetics and molecular biology (all) Biochemistry & molecular biology
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: nil.novau@urv.cat melina.rojas@estudiants.urv.cat laia.gutierrez@urv.cat monica.bullo@urv.cat jaume.folch@urv.cat
    Author identifier: 0000-0002-0218-7046 0000-0002-5051-8858
    Record's date: 2024-10-12
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://cellandbioscience.biomedcentral.com/articles/10.1186/s13578-023-01190-5#citeas
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Cell And Bioscience. 14 (1): 8-8
    APA: Gutierrez-Tordera, Laia; Papandreou, Christopher; Novau-Ferre, Nil; Garcia-Gonzalez, Pablo; Rojas, Melina; Marquie, Marta; Chapado, Luis A; Papagianno (2024). Exploring small non-coding RNAs as blood-based biomarkers to predict Alzheimer's disease. Cell And Bioscience, 14(1), 8-8. DOI: 10.1186/s13578-023-01190-5
    Article's DOI: 10.1186/s13578-023-01190-5
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2024
    Publication Type: Journal Publications
  • Keywords:

    Biochemistry & Molecular Biology,Biochemistry, Genetics and Molecular Biology (Miscellaneous)
    Small non-coding rna
    Potential biomarkers
    Nested case–control study
    Mild cognitive impairment
    Gene regulatory networks
    Biomarkers
    Atn
    Alzheimer’s disease
    Alzheimer's disease
    tau
    small non-coding rna
    performance
    nested case-control study
    mirnas
    mild cognitive impairment
    gene regulatory networks
    expression
    diagnosis
    biomarkers
    atn
    Medicina ii
    General biochemistry,genetics and molecular biology
    Biochemistry, genetics and molecular biology (miscellaneous)
    Biochemistry, genetics and molecular biology (all)
    Biochemistry & molecular biology
  • Documents:

  • Cerca a google

    Search to google scholar